Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317210 | 0.88 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL4098095 | 0.82 | P2RY12 (0.61) | P2RY12 | |
| SCHEMBL4500021 | 0.81 | CXCR3 (0.43) | P2RY12CXCR3 | |
| SCHEMBL4518854 | 0.80 | CXCR3 (0.44) | P2RY12CXCR3 | |
| SCHEMBL4508825 | 0.78 | GRM4 (0.42) | CXCR3SLC6A7 | |
| SCHEMBL4508778 | 0.78 | NPY2R (0.38) | P2RY12CXCR3SLC6A7 | |
| SCHEMBL4522607 | 0.76 | CXCR3 (0.44) | P2RY12CXCR3SLC6A7 | |
| SCHEMBL4105686 | 0.74 | P2RY12 (0.58) | P2RY12 | |
| SCHEMBL5592425 | 0.74 | P2RY12 (0.54) | P2RY12 | |
| SCHEMBL15992614 | 0.74 | TRPV1 (0.40) | P2RY12CXCR3SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CXCR3 962/4885SLC6A7 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.